Splenic Rupture as a Complication of Autologous Hematopoietic Cell Transplantation In a Patient with Systemic Amyloidosis.

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4528-4528 ◽  
Author(s):  
Taiga Nishihori ◽  
Noman Ashraf ◽  
Estrella M. Carballido ◽  
Timothy Yeatman ◽  
Lynn C. Moscinski ◽  
...  

Abstract Abstract 4528 Background: Atraumatic splenic rupture is a known complication of amyloidosis. We report a female patient with amyloidosis who developed spontaneous splenic rupture in the peri transplant period. Case report: A 56 years old Caucasian woman presented with renal failure (creatinine 1.7 mg/dL) and nephrotic-range proteinuria (3.6 grams in 24 hours). Renal biopsy showed mesangial expansion with increased diffuse infiltrate and Congo red stain positivity consistent with renal amyloidosis. Bone marrow (BM) biopsy showed 5% plasma cells. Pre-transplant CT scan showed hepatosplenomegaly. 13.16 million CD34+ cells/kg of G-CSF mobilized progenitor cells were collected without complications. She received high dose melphalan at 200 mg/m2 followed by autologous hematopoietic cell transplantation (HCT). On post transplant day +8, she developed initial intraperitoneal hemorrhage from spontaneous splenic rupture. The post-transplant course was complicated with tracheal intubation, worsening renal failure requiring hemodialysis, and episodic hypertensive episodes with posterior reversible encephalopathy syndrome, making her a poor candidate for immediate surgical intervention. A day +60 BM biopsy showed normal cellularity with mild megakaryocytic hyperplasia. There was amyloid deposition in 30% of marrow space by Congo red stain. She underwent exploratory laparotomy and splenectomy on day +70 post transplant. Spleen was enlarged, measuring 18 × 15 × 9 cm in size, and weighed 1630 grams. There were multiple areas of hemorrhage and necrosis with multifocal and extensive nodular deposition of pink, amorphous, and waxy material. Congo red stain showed apple-green birefringence in associated collagen and vessel walls. Thioflavin T was strongly positive, confirming the presence of amyloid. No evidence of lymphoproliferative disorder or plasma cell dyscrasia was seen. The patient developed rebleeding and was treated with aminocaproic acid and multiple platelet transfusions. Her post transplant course has been further complicated with the development of autoimmune hemolytic anemia and immune thrombocytopenic purpura, consistent with Evans syndrome. She required treatment with corticosteroids, intravenous immunoglobulin, rituximab and colchicine. More than five months from her transplant, the patient is alive, independent of transfusion support, and in complete remission. Discussion: Splenic involvement in amyloidosis is rather frequent (5-10%). However, an atraumatic rupture of the affected spleen is thought to be an extremely rare event. There have been only 5 published cases of spontaneous splenic rupture in the context of autologous HCT in patients with amyloidosis (Am J Hematol 2003;74:131-135, Eur J Haematol 2008;80:182-184, Wien Klin Wochenschr 2006;118:49-53). One case was associated with G-CSF stem cell mobilization. The range of timing of splenic rupture in reported cases was day +1 to +23 post transplant. The reported spleen weight ranged from 159 to 450 grams. Most patients had elevated white blood cell count at the time of rupture. Although the occurrence of atraumatic splenic rupture in amyloid patients has been described, spontaneous splenic rupture in the context of autologous HCT still remains rare. Transplant physicians should maintain high index of suspicion for spontaneous splenic rupture in amyloid patients and laparoscopic splenectomy can be safely performed in the post-transplant period granted that their cardiac status can tolerate pneumoperitoneum. Disclosures: No relevant conflicts of interest to declare.

2005 ◽  
Vol 23 (27) ◽  
pp. 6699-6711 ◽  
Author(s):  
Ravi Bhatia ◽  
Khristine Van Heijzen ◽  
Ann Palmer ◽  
Asako Komiya ◽  
Marilyn L. Slovak ◽  
...  

Purpose Autologous hematopoietic cell transplantation (HCT) is being increasingly used as an effective treatment strategy for patients with relapsed or refractory Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL) but is associated with therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) as a major cause of nonrelapse mortality. The phenomenon of hematopoietic reconstitution after autologous HCT and the role of proliferative stress in the pathogenesis of t-MDS/AML are poorly understood. Patients and Methods Using a prospective longitudinal study design, we evaluated the nature and timing of alterations in hematopoietic progenitors and telomere length after HCT in patients undergoing autologous HCT at City of Hope Cancer Center (Duarte, CA). Results A significant reduction in primitive and committed progenitors was observed before HCT compared with healthy controls. Further profound and persistent reduction in primitive progenitors but only transient reduction in committed progenitors were seen after HCT. Primitive progenitor frequency in pre-HCT marrow and peripheral-blood stem cells predicted for primitive progenitor recovery after HCT. Shortening of telomere length was observed in marrow cells early after HCT, with subsequent restoration to pre-HCT levels. Patients within this cohort who developed t-MDS/AML had reduced recovery of committed progenitors and poorer telomere recovery, possibly indicating a functional defect in primitive hematopoietic cells. Conclusion Our studies suggest that hematopoietic regeneration after HCT is associated with increased proliferation and differentiation of primitive progenitors. Increased proliferative stress on stem cells bearing genotoxic damage could contribute to the pathogenesis of t-MDS/AML. Extended follow-up of a larger number of patients is required to confirm whether alterations in progenitor and telomere recovery predict for increased risk of t-MDS/AML.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 832-832 ◽  
Author(s):  
Neil Dunavin ◽  
Lih-Wen Mau ◽  
Christa Lea Meyer ◽  
Clint Divine ◽  
Al-Ola Abdallah ◽  
...  

Abstract Introduction: Inpatient services are the leading drivers of cost for autologous hematopoietic cell transplantation (HCT), and the number of Medicare beneficiaries who receive autologous HCT is increasing. Using a merged dataset of Center for International Blood and Marrow Transplant Research (CIBMTR) transplant and outcomes data and Centers for Medicare and Medicaid Services (CMS) Medicare administrative claims data, we examined reimbursement and service utilization among Medicare beneficiaries with multiple myeloma (MM) who received IP and OP autologous HCT. Methods: This was a multicenter retrospective cohort study. A total of 11,358 HCT recipients from 2010-2012 were identified in the CMS Medicare database; 9,055 (80%) were linked with CIBMTR data. Selection criteria included first HCT for MM, diagnosis-to-HCT time between 0 and 18 months, and continuous enrollment for 30 days prior to index and 100 days post-HCT or until death. For IP-HCT, the index period for reimbursement and service utilization was day of admission for HCT through discharge date. For OP-HCT, the index period was day -2 through HCT date to capture the conditioning regimen. Total IP and OP service days from 30 days prior to index and 100 days post-HCT, and subsequent admissions post the HCT index period were calculated. Total reimbursement consisted of all payments made to providers (Medicare payments for Part A & B services, secondary payer, and patient responsibility of deductibles, coinsurance, and copayments), which was adjusted by a weighted generalized linear model (GLM). Patient responsibility was assessed separately and adjusted by the same GLM. Kaplan-Meier method was used for overall survival (OS) analysis; potential factors associated with OS were adjusted by Cox regression modeling. Results: The final cohort comprised 1,640 patients; 1,445 (88%) received IP-HCT (126 centers) and 195 (12%) OP-HCT (24 centers). Patient characteristics, functional status, disease status, and HCT year were similar between groups except a higher percentage of IP-HCT recipients were 70 years and older (IP-HCT: 31%, OP-HCT: 19%; P=0.0003), and a lower percentage of IP-HCT recipients received full dose melphalan 200 mg/m2 (IP-HCT: 68%, OP-HCT: 90%; P=0.0036). There was a significant difference between the cohorts in the utilization of IP services (IP-HCT group: median 19 days, OP-HCT group: 4 days; P < 0.0001) and OP services (IP-HCT group: median 16 days, OP-HCT group: 33 days; P < 0.0001) at day 100. Adjusted total mean reimbursement for the IP-HCT group ($83,380 [95% CI: $78,958-$88,051]) was higher than the OP-HCT group ($55,721 [95% CI: $38,595-$80,446]) (P= 0.0301) (Figure). Factors associated with total reimbursement in the GLM were transplant setting, age, sex, comorbidity index, diagnosis-to-HCT time, and melphalan dose. Adjusted total patient responsibility for the IP-HCT group was $4,567 (95% CI: $4,210- $4,955) and $7,372 ($4,218- $12,884) (P=0.0902) for the OP-HCT group. Within 100 days post-HCT, 107/195 (55%) OP-HCT recipients had at least one subsequent admission, compared to 348/1,445 (24%) IP-HCT recipients (P < 0.0001). OS at 100 days was high for both HCT settings and adjusted OS was not significantly different by transplant setting (IP-HCT 98% [95% CI: 97%-99%]; OP-HCT 99% [95% CI: 98%-100%; P=0.1903) Conclusions: Reimbursement and service utilization varied by HCT setting for Medicare beneficiaries with MM. Total reimbursement for 100 days post-HCT was $27,659 higher for IP-HCT than OP-HCT, after adjusting for patient and HCT-related characteristics. After the HCT index period, approximately 1 in 4 IP-HCT recipients required re-hospitalization within 100 days, whereas 1 in 2 OP-HCT recipients required subsequent hospitalization. Many factors influence the decision between IP or OP autologous HCT, including: center experience, severity of disease, patient co-morbidities, access to caregivers, proximity of lodging, cost to the patient, and reimbursement for services to the hospital system. The CIBMTR-CMS merged database is a new resource to support ongoing efforts to inform transplant centers and healthcare systems about provision of care options in the Medicare population. Figure. Figure. Disclosures Ganguly: Janssen: Consultancy; Amgen: Consultancy; Seattle Genetics: Speakers Bureau; Daiichi Sankyo: Research Funding.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 3189-3189
Author(s):  
Taiga Nishihori ◽  
Rachid Baz ◽  
Leonel Ochoa ◽  
Omar Alexis Castaneda Puglianini ◽  
Kenneth H. Shain ◽  
...  

Background: Autologous hematopoietic cell transplantation (HCT) followed by maintenance therapy with an immunomodulatory agent or a proteasome inhibitor remains an important strategy for upfront treatment in multiple myeloma (MM) with progression-free survival (PFS) and overall survival (OS) advantage. We designed a two-arm, open-label prospective study to examine the safety and tolerability of two different dosing schedules of an oral pan-histone deacetylase inhibitor, panobinostat (pano) as an alternative maintenance therapy option in patients with MM (NCT02722941). Methods: A total of 30 MM patients who underwent autologous HCT within the preceding 90 to 180 days were enrolled at Moffitt Cancer Center using a sequential alternating allocation to starting dose of either Cohort A: 20 mg PO 3/week, q 2 weeks on a 28-day cycle, or Cohort B: 10 mg PO daily for 7 days, q 2 weeks on a 28-day cycle, for 12 cycles. Dose level -1 was cohort A: 15 mg 3/week; and cohort B: 10 mg 4/week. Patients with clinically significant cardiac diseases, bradycardia, QTc > 470 msec, bifascicular block were ineligible. EKG was performed on pre- and post-dose on day 1 & 5 of cycle 1, and pre-dose on day 1 of cycles 2-4. Relative dose intensity (RDI), a ratio of amount of drug actually delivered in mg over the amount of planned dose in mg, was calculated to evaluate the treatment feasibility as a surrogate measure. Results: The median age of the entire cohort was 60 (range, 40-73) years with a male/female = 18/12. Disease characteristics are summarized in the Table. Patients initiated pano maintenance at a median of 131 (range 91 - 178) days after autologous HCT. As of 8/1/2019, 16 patients (8 in each cohort) completed full 12 cycles of pano. The RDI for the entire cohort, cohort A, and cohort B was 94.1% (33,750mg/35,860, 98% (16,350mg/16,680mg), and 90.7% (17,400mg/19,180mg), respectively. One patient in cohort A had dose reduction, and 6 patients in cohort B had dose reductions with cytopenias (43%) and GI toxicities (43%) being the most common reasons. No patients required dose modifications due to QT prolongation thus far. There were 3 possibly treatment-associated serious adverse events (pneumonia=2; colitis=1) but all patients successfully resumed pano. Three patients progressed while on pano maintenance. No mortality has been observed thus far. Ten patients are still on pano treatment. The median follow-up is 11 (range, 1-29) months. Conclusions: RDI is 90% overall and panobinostat as a single oral maintenance agent either at 20 mg three times per week or 10 mg po daily for 7 days on alternating weeks appears to be overall well tolerated. There were more dose reductions required in the 10 mg starting dose (cohort B). Panobinostat is a safe alternative for maintenance therapy after autologous HCT. Longer follow-up is needed to confirm the utility of this approach and updated results will be presented at the meeting. Disclosures Nishihori: Novartis: Research Funding; Karyopharm: Research Funding. Baz:Sanofi: Research Funding; Bristol-Myers Squibb: Research Funding; AbbVie: Research Funding; Merck: Research Funding; Celgene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Research Funding. Shain:Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; AbbVie: Research Funding; Sanofi Genzyme: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Adaptive Biotechnologies: Consultancy. Brayer:Janssen: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau. Locke:Kite: Other: Scientific Advisor; Novartis: Other: Scientific Advisor; Cellular BioMedicine Group Inc.: Consultancy. Alsina:Bristol-Myers Squibb: Research Funding; Janssen: Speakers Bureau; Amgen: Speakers Bureau. OffLabel Disclosure: Panobinostat single agent maintenance therapy after autologous hematopoietic cell transplantation for multiple myeloma


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3168-3168
Author(s):  
Arun Singavi ◽  
Jonathan Kapke ◽  
Adam Levin ◽  
Anjishnu Banerjee ◽  
Fenlu Zhu ◽  
...  

Abstract Background: High-dose therapy with autologous hematopoietic cell transplantation (autoHCT) is now well established as an effective therapy for lymphoma. However, infection is a known risk of autoHCT. Following autoHCT, prolonged lymphopenia (PL) and hypogammaglobulinemia (HypoGG) can occur and lead to a significant acquired immunodeficiency. While early recovery of lymphocyte count has been found to be a predictor of overall survival post autoHCT, the risk factors for and effects of PL and HypoGG in this population have not been carefully studied. Methods: We retrospectively reviewed all lymphoma patients who received their first autoHCT at the Medical College of Wisconsin from January 2009-December 2013. Patient charts were abstracted for pre-transplant disease characteristics (including lines of chemotherapy and regimens received prior to HCT, rituximab use, absolute lymphocyte count (ALC) pre-HCT, CD34+ and lymphocytes infused with HCT product) and post-transplant outcomes including day 100 ALC, 1 year IgG/A/M levels, and serious infections (SI). SI was defined as bacteremia, pneumonia, meningitis, pneumonia, clostridium difficile, neutropenic fever; or any infection requiring admission; or 2 or more infections of any type. Primary outcomes of interest included whether SI correlated with Day 100 ALC and 1 year IgG/A/M levels. Survival outcomes (time to SI) were estimated using Kaplan Meier method, and comparisons made with Fisher's exact test, Chi-square tests, and log rank test. Multivariable analysis (MVA) was performed using the Cox proportional hazard regression. P-values of less than 0.05 were considered significant. Results: A total of 161 patients were included, of which 29 patients were excluded due to early relapse. Of the remaining 132 patients, 50 developed SI. Comparing the two groups (Table 1 - SI vs no SI), the majority of patients in both groups were Hodgkin Lymphoma, DLBCL, MCL, and FL with advanced stages at diagnosis. Prior to transplant, patients underwent >2 lines of chemotherapy and the majority were in complete remission at the time of transplant. Patients treated with HyperCVAD had a higher rate of SI (p<0.01) and ABVD had lower SI rate (p<0.01). 86 patients were treated with rituximab, with no difference in SI for total doses received or proximity to transplant. There was no association of ALC prior to transplant, CD34 infused, or lymphocytes infused with SI. Post-transplant, patients with low day 100 ALC (p=0.04) and low 1 year IgM (p<0.01) had significantly higher rates of SI. This difference was retained on multivariate analysis. Interestingly, IgG level at 1 year did not predict for SI. Conclusion: We conclude that, following autoHCT, lymphoma patients with a day 100 ALC < 1200 or 1 year IgM < 60 are at significantly higher risk for SI. Contrary to our original hypothesis, day 100 ALC didnot correlate with 1 year Ig G/A/M levels. Other cell types, such as helper T cells and regulatory T cells, may also contribute to effective reconstitution of humoral immunity, such that ALC alone may not be a reliable predictor of immunoglobulin recovery. Further prospective studies looking at subsets of lymphocytes, including B cells, T cell subsets, and NK cells may be helpful in identifying patients at significant risk for serious infections post autoHCT. Disclosures Hamadani: Celgene: Consultancy; Takeda: Research Funding; MedImmune: Consultancy; Cellerant: Consultancy. Hari:Janssen: Consultancy; Novartis: Consultancy; Spectrum: Consultancy; Sanofi: Consultancy; Takeda: Consultancy; Celgene: Consultancy; BMS: Consultancy. Fenske:Celgene: Honoraria; Seattle Genetics: Honoraria; Millennium/Takeda: Research Funding; Pharmacyclics: Honoraria.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5816-5816
Author(s):  
Haitham Abdelhakim ◽  
Sajjad Akbar Bhatti ◽  
Amy Rose Cantilena ◽  
Tara L. Lin ◽  
Siddhartha Ganguly ◽  
...  

Abstract High-dose chemotherapy and autologous hematopoietic cell transplantation (Auto-HCT) is an established therapy for patients with multiple myeloma and lymphomas. Post-transplant complications during the neutropenia phase include pancytopenia requiring transfusions and G-CSF support, mucositis and infectious complications. Previously, we have demonstrated that hyperbaric oxygen therapy (HBO) given day 0 prior to transplant reduced erythropoietin (EPO) levels and improved engraftment in umbilical cord blood transplantation. Subsequently, we conducted a pilot trial to study HBO effects EPO levels and engraftment in Auto-HCT setting. Herein, we review HBO effects on Auto-HCT post-transplant complications. Methods: Charts of patient who underwent HBO treatment prior to Auto-HCT on our pilot study and matched historic controls were retrospectively reviewed for post-transplant transfusion requirements, G-CSF support, mucositis and infectious complications Results: Nineteen patients completed HBO therapy and were compared to 118 patients in our historic cohort. Basic patient characteristics are listed in table-1. Average days of G-CSF use was 6.2 days in our HBO cohort compared to 9.16 days in the historic cohort (P=0.0007). Average number of transfused packed red cells was 2.1 and 2.58 units (P=0.22), while average number of platelet unit transfusions was 2.5 and 3.2 (P=0.17) in the HBO and historic cohorts, respectively. Mucositis incidence was 26.3% in the HBO cohort compared to 59.3% in controls (P=0.008). Similarly, the rate of neutropenic fever was 47% in the HBO cohort vs. 65% in controls (P=0.11). The rate of admissions, on the other hand, was 31.5% in the HBO cohort compared to 23.7% in controls (P=0.31) with an average length of hospital stay of 6.6 days in the HBO cohort compared to 7.68 days in controls (P=0.31). Conclusions: HBO therapy prior to Auto-HCT is associated with lower G-CSF use and lower incidence of mucositis in our retrospective study. Prospective studies are needed to determine HBO effects on Auto-HCT post-transplant complications. Disclosures Ganguly: Onyx: Speakers Bureau; Seattle Genetics: Speakers Bureau; Janssen: Research Funding.


2017 ◽  
Vol 1 (12) ◽  
pp. 707-714 ◽  
Author(s):  
Ang Li ◽  
Chris Davis ◽  
Qian Wu ◽  
Shan Li ◽  
Madeline F. Kesten ◽  
...  

Key Points Anticoagulation continuation vs cessation during thrombocytopenia did not affect recurrent thrombosis or bleeding after autologous HCT. Among anticoagulated patients undergoing autologous HCT, higher platelet counts were not associated with a lower risk of bleeding.


Blood ◽  
2013 ◽  
Vol 121 (16) ◽  
pp. 3095-3102 ◽  
Author(s):  
Masamitsu Yanada ◽  
Motohiro Tsuzuki ◽  
Hiroyuki Fujita ◽  
Katsumichi Fujimaki ◽  
Shin Fujisawa ◽  
...  

Key Points We conducted a phase 2 study of ATO followed by autologous HCT for relapsed APL. This sequential treatment is effective and feasible.


2017 ◽  
Vol 137 (3) ◽  
pp. 117-122 ◽  
Author(s):  
Yun Liang ◽  
Jie Gao ◽  
Dan Wu ◽  
Shu Li ◽  
Hang Chen ◽  
...  

Multiple nonleukemic myeloid sarcoma (MS) is a rare form of MS that is developed in multiple anatomic sites other than bone marrow at diagnosis, without a preceding myeloid neoplasm. The prevalence, prognosis, and optimal management of multiple nonleukemic MS have not been addressed. The role of allogenic or autologous hematopoietic cell transplantation (HCT) for nonleukemic MS is also less well defined. We present a case of MS characterized by systemic lymphadenopathies and multiple effusions, which presumably had a very poor prognosis. The patient was treated with acute myeloid leukemia-type induction chemotherapy and autologous peripheral blood stem cell transplantation, and, unexpectedly, she has remained disease free for more than 6 years. We also reviewed the literature on this rare disease, and found that multiple nonleukemic MS was associated with younger age and a worse prognosis when compared with the overall nonleukemic MS population. We suggest that autologous HCT represents a valid option for young patients with chemosensitive disease and should be performed at the status of minimal residual disease-negative complete remission.


Sign in / Sign up

Export Citation Format

Share Document